Key Points
- CEO Steven Leonard Chapman sold 3,848 Natera shares on January 2 at an average price of $229.08 for a total of $881,499.84, trimming his stake by 2.74% to 136,568 shares (≈$31.28M).
- The Jan. 2 sale is part of a series of recent insider dispositions, including a notably large November 3 sale of 160,703 shares for about $32.13M, indicating ongoing executive selling.
- For context, Natera shares are trading near their one‑year high (~$249) with a $34.4B market cap; the company reported a quarterly loss (EPS -$0.64) but revenue rose 34.7% year‑over‑year and analysts have a consensus "Moderate Buy" target of about $235.29.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 2,951 shares of the business's stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $228.95, for a total transaction of $675,631.45. Following the sale, the insider owned 123,499 shares in the company, valued at $28,275,096.05. This trade represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Solomon Moshkevich also recently made the following trade(s):
- On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The shares were sold at an average price of $230.76, for a total transaction of $1,082,725.92.
- On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $238.15, for a total transaction of $714,450.00.
- On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $198.60, for a total value of $595,800.00.
- On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The stock was sold at an average price of $191.46, for a total value of $229,369.08.
- On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The stock was sold at an average price of $192.32, for a total transaction of $193,858.56.
- On Tuesday, October 21st, Solomon Moshkevich sold 292 shares of Natera stock. The shares were sold at an average price of $187.95, for a total transaction of $54,881.40.
Natera Trading Up 4.8%
Shares of NTRA stock opened at $248.74 on Wednesday. The firm has a fifty day moving average price of $224.18 and a 200 day moving average price of $184.78. The company has a market cap of $34.41 billion, a P/E ratio of -108.62 and a beta of 1.62. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $249.15.
Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The business had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.Natera's revenue was up 34.7% on a year-over-year basis. During the same period last year, the business posted ($0.26) EPS. On average, equities analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Horizon Investments LLC acquired a new stake in shares of Natera during the 3rd quarter valued at approximately $32,000. Northwestern Mutual Wealth Management Co. raised its holdings in Natera by 83.5% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company's stock worth $33,000 after purchasing an additional 106 shares during the last quarter. Hilltop National Bank purchased a new stake in Natera during the second quarter worth $33,000. Oliver Lagore Vanvalin Investment Group purchased a new stake in Natera during the second quarter worth $36,000. Finally, Sound Income Strategies LLC increased its position in shares of Natera by 95.7% in the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company's stock valued at $39,000 after buying an additional 110 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the company. Zacks Research upgraded Natera from a "strong sell" rating to a "hold" rating in a research note on Thursday, January 1st. Stephens increased their price target on Natera from $197.00 to $235.00 and gave the stock an "overweight" rating in a report on Thursday, November 13th. UBS Group boosted their price objective on shares of Natera from $218.00 to $280.00 and gave the company a "buy" rating in a research note on Tuesday, November 18th. Morgan Stanley raised their price objective on shares of Natera from $220.00 to $265.00 and gave the company an "overweight" rating in a research report on Monday, December 1st. Finally, Guggenheim boosted their target price on Natera from $230.00 to $270.00 and gave the stock a "buy" rating in a research report on Monday. Sixteen investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $235.29.
Read Our Latest Stock Report on Natera
Natera Company Profile
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
